# OnCo record nct05379985 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct05379985/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct05379985", "NCT05379985" ;
  schema:name "Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS"@en ;
  schema:alternateName "RMC-6236-001"@en, "Daraxonrasib phase 1/2"@en ;
  schema:description "A phase 1/2 trial of Daraxonrasib in non-small-cell lung cancer and small-cell lung cancer, run by Revolution Medicines, Inc., now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct05379985/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05379985>, <https://doi.org/10.1056/NEJMoa2505783> ;
  onco:status "recruiting" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "1/2" ;
  schema:startDate "2022-05-31" ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/sclc/>, <https://onco.cc/cancers/colorectal/>, <https://onco.cc/cancers/pancreatic/>, <https://onco.cc/cancers/metastatic-pdac/> ;
  onco:technologies <https://onco.cc/technologies/kras-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/daraxonrasib/> ;
  onco:companies <https://onco.cc/companies/revolution-medicines/> ;
  onco:terms <https://onco.cc/terms/kras-mutation-subtypes/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-nct05379985-n-engl-j-med-2026/> .